膀胱癌本质上具有异质性，表现出不同的分子谱和组织病理学特征，这给诊断和治疗带来了挑战。然而，了解这种异质性的分子基础仍然难以捉摸。本研究旨在阐明神经内分泌样膀胱肿瘤的分子景观，重点关注 β-连环蛋白定位的参与。通过分析转录组数据并受益于分子分类工具，我们对肌肉浸润性膀胱癌进行了深入分析，以揭示神经内分泌样分化的分子特征。该研究探讨了转录因子和染色质重塑复合物对膀胱癌神经内分泌分化的贡献。该研究揭示了肌层浸润性膀胱肿瘤中β-连环蛋白定位与神经内分泌分化之间的显着相关性，凸显了神经内分泌样肿瘤的分子复杂性。 β-连环蛋白阳性肿瘤中 YY1 转录因子、E2F 家族成员和 Polycomb 抑制复合物成分的富集表明它们对神经内分泌表型的潜在贡献。我们的研究结果为了解神经内分泌样膀胱肿瘤的分子复杂性提供了宝贵的见解。通过确定潜在的治疗靶点和完善诊断策略，这项研究增进了我们对膀胱癌内分泌学的理解。有必要进一步研究这些分子关系的功能含义，以增强我们的知识并指导未来的治疗干预。© 2024 作者。约翰·威利出版的《癌症科学》

Bladder cancers are heterogeneous in nature, showing diverse molecular profiles and histopathological characteristics, which pose challenges for diagnosis and treatment. However, understanding the molecular basis of such heterogeneity has remained elusive. This study aimed to elucidate the molecular landscape of neuroendocrine-like bladder tumors, focusing on the involvement of β-catenin localization. Analyzing the transcriptome data and benefiting from the molecular classification tool, we undertook an in-depth analysis of muscle-invasive bladder cancers to uncover the molecular characteristics of the neuroendocrine-like differentiation. The study explored the contribution of transcription factors and chromatin remodeling complexes to neuroendocrine differentiation in bladder cancer. The study revealed a significant correlation between β-catenin localization and neuroendocrine differentiation in muscle-invasive bladder tumors, highlighting the molecular complexity of neuroendocrine-like tumors. Enrichment of YY1 transcription factor, E2F family members, and Polycomb repressive complex components in β-catenin-positive tumors suggest their potential contribution to neuroendocrine phenotypes. Our findings contribute valuable insights into the molecular complexity of neuroendocrine-like bladder tumors. By identifying potential therapeutic targets and refining diagnostic strategies, this study advances our understanding of endocrinology in the context of bladder cancer. Further investigations into the functional implications of these molecular relationships are warranted to enhance our knowledge and guide future therapeutic interventions.© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.